Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

New Tecartus Ph2 Trial (ZUMA-25) for R/R Rare B-cell Malignancies

Here is a brief preview of this blast: On Tuesday, September 13, a new Gilead / Kite-sponsored Ph2 trial (ZUMA-25) evaluating Tecartus (autologous CD19 CAR-T) in rare B-cell malignancies was observed on CT.gov. Below, Celltelligence provides details for this trial while discussing how Gilead could leverage Tecartus’s indication expansion strategy to differentiate from its main competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.